The present disclosure is directed to compositions and methods for the treatment or prevention of viral infections and diseases or conditions associated with viral infections. Among other things, the present disclosure encompasses the insight that redundant targeting of multiple pathways essential for viral infection and replication provides effective treatment and prevention of viral infection.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
The present invention is directed to compositions and methods for the treatment of cancers, particularly cancers of epithelial origin. Therapy with a plurality of nutraceutical, non-chemotherapeutic and chemotherapeutic agents, that together target a plurality of cancer-supportive processes in a patient are disclosed. Among other things, the present invention encompasses the insight that redundant targeting of multiple such pathways provides effective treatment of various cancer, including late-stage cancers, metastasized cancers, and/or cancers that have failed treatment with traditional chemotherapy and/or other therapeutic modalities.
A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
A61K 31/385 - Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
A61K 31/4045 - Indole-alkylaminesAmides thereof, e.g. serotonin, melatonin
A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A61K 38/33 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
Pharmaceutical preparations for treatment of cancer; nutraceutical preparations for treatment of cancer; pharmaceutical preparations for treatment of infectious diseases, namely, Covid-19; pharmaceutical preparations for prophylaxis of infectious diseases, namely, Covid-19 Pharmaceutical and nutraceutical research and development; providing medical and scientific research information in the field of pharmaceuticals and nutraceuticals, and clinical trials and post-market trials related to pharmaceuticals and nutraceuticals
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
Pharmaceutical preparations for treatment of cancer; nutraceutical preparations for treatment of cancer; pharmaceutical preparations for treatment of infectious diseases, namely, Covid-19; pharmaceutical preparations for prophylaxis of infectious diseases, namely, Covid-19 Pharmaceutical and nutraceutical research and development; providing medical and scientific research information in the field of pharmaceuticals and nutraceuticals, and clinical trials and post-market trials related to pharmaceuticals and nutraceuticals
5.
COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF VIRAL INFECTIONS
The present disclosure is directed to compositions and methods for the treatment or prevention of viral infections and diseases or conditions associated with viral infections. Among other things, the present disclosure encompasses the insight that redundant targeting of multiple pathways essential for viral infection and replication provides effective treatment and prevention of viral infection.
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Diagnostic kits consisting primarily of diagnostic reagents and instructions sold as a unit for medical diagnostic uses; pharmaceutical products, namely, drugs that directly and indirectly influence angiogenesis and its regulation; nutraceutical products, namely, nutritional supplements; dietary supplements. Development of medical diagnostic test kits for others; medical information services, namely, clinical laboratory testing services for research purposes, for physicians, other medical professionals and consumers. Medical information services, namely, clinical laboratory testing services for diagnostic or treatment purposes, for physicians, other medical professionals and consumers.
The present invention is directed to compositions and methods for the treatment of cancers, particularly cancers of epithelial origin. Therapy with a plurality of nutraceutical, non-chemotherapeutic and chemotherapeutic agents, that together target a plurality of cancer-supportive processes in a patient are disclosed. Among other things, the present invention encompasses the insight that redundant targeting of multiple such pathways provides effective treatment of various cancer, including late-stage cancers, metastasized cancers, and/or cancers that have failed treatment with traditional chemotherapy and/or other therapeutic modalities.
A61K 31/385 - Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
A61K 31/382 - Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
A61K 31/4045 - Indole-alkylaminesAmides thereof, e.g. serotonin, melatonin
A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A61K 38/33 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
The present invention is directed to compositions and methods for the treatment of cancers, particularly cancers of epithelial origin. Therapy with a plurality of nutraceutical, non-chemotherapeutic and chemotherapeutic agents, that together target a plurality of cancer-supportive processes in a patient are disclosed. Among other things, the present invention encompasses the insight that redundant targeting of multiple such pathways provides effective treatment of various cancer, including late-stage cancers, metastasized cancers, and/or cancers that have failed treatment with traditional chemotherapy and/or other therapeutic modalities.
A61K 31/385 - Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
A61K 31/4045 - Indole-alkylaminesAmides thereof, e.g. serotonin, melatonin
A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A61K 38/33 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
(1) Diagnostic kits consisting primarily of diagnostic reagents and instructions sold as a unit for medical diagnostic uses; pharmaceutical products, namely, drugs that directly and indirectly influence angiogenesis and its regulation; nutraceutical products, namely, nutritional supplements for oncology and general health and well-being; dietary supplements for oncology and general health and well-being. (1) Development of medical diagnostic test kits for others; medical information services, namely, clinical laboratory testing services for research purposes, for physicians, other medical professionals and consumers; medical information services, namely, clinical laboratory testing services for diagnostic or treatment purposes, for physicians, other medical professionals and consumers.
10.
TREATMENT FOR PANCREATIC ADENOCARCINOMA AND OTHER CANCERS OF EPITHELIAL ORIGIN
The present invention is directed to compositions and methods for the treatment of pancreatic cancer. Compositions comprising a plurality of nutraceutical and non-chemotherapeutic drug components directed to addressing cancer-supportive processes in a patient are disclosed.
